FENNEC PHARMACEUTICALS INC.

Fennec Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company operating in the United States. The company's primary product candidate is PEDMARK, a specialized formulation of sodium thiosulfate. This product is designed to prevent ototoxicity, which is hearing damage, in pediatric patients undergoing treatment with cisplatin, a chemotherapy drug. Fennec Pharmaceuticals Inc. distributes its products through regional pediatric oncology specialists and medical science liaisons. The company has established collaborations, including one with Tampa General Hospital Foundation, Inc. This collaboration focuses on evaluating the clinical usefulness of sodium thiosulfate injection in reducing the risk of ototoxicity in adolescent, young adult, and adult cancer patients who are receiving cisplatin-based treatment. Fennec Pharmaceuticals Inc. also has a collaboration with Norgine Pharma UK Limited. The company was incorporated in 1996 and is headquartered in Research Triangle Park, North Carolina. It was formerly known as Adherex Technologies Inc. and adopted the name Fennec Pharmaceuticals Inc. in September 2014.